ONGOING TRIALS

MAKING A COMMITMENT TO YOU AND YOUR PATIENTS

Two ongoing trials studying long-term safety and efficacy of SPEVIGO1,2
Real SPEVIGO® patient. Lesions shown have been created with makeup for illustrative purposes only and do not reflect the patient’s current condition.

Ongoing trials

EFFISAYIL® ON

An open-label extension study to evaluate the long-term safety and efficacy of intravenous and subcutaneous spesolimab in patients with generalized pustular psoriasis (GPP) who have completed previous spesolimab trials1

Interim analysis presented at AAD 2026

EFFISAYIL® REP

An open-label, single-arm, Phase 4 trial to evaluate the efficacy, safety, and impact of immunogenicity in the treatment of patients with GPP presenting with a recurrent flare following their initial GPP flare treatment with intravenous spesolimab2

AAD, American Academy of Dermatology.